

1 **Title:** Caesarean myomectomy is not a risk factor for blood products transfusion among pregnant
2 individuals with fibroids: a retrospective cohort study.

3 **Authors:** Jarvi S¹, Aviram A¹, Joliffe C¹, Wortsman S¹, Liu GY¹, Berndl A¹, Barrett J¹, Kroft J¹

4 ¹Department of Obstetrics and Gynaecology, Sunnybrook Health Sciences Centre, University of
5 Toronto, Canada

6
7 **Disclosures:** The authors report no conflict of interest. JK was on the speakers bureaus and
8 receives consulting fees from Abbvie corporation and Pfizer, consulting fees from Ethicon and
9 Organon

10 **Funding:** No sources of funding

11 **Presentation:** No presentations

12 **Disclaimer:** None

13 **Corresponding Author:** Stephanie Jarvi. Address: Sunnybrook Health Sciences Centre 2075
14 Bayview Avenue, North York, ON M4N 3M5.

15 **Acknowledgements:** None

16

17 **ABSTRACT**

18 Background: Uterine fibroids are common benign tumors during reproductive age. Among
19 pregnant individuals with uterine fibroids, myomectomy at the time of cesarean delivery (CD)
20 allows individuals to avoid a second surgery later in life.

21 Objective: To examine the safety of myomectomy performed at the time of CD and the factors
22 that increase the risk of greater blood loss in cesarean myomectomy.

23 Study design: This was a retrospective cohort study of all cesarean myomectomies (CM)
24 performed at a tertiary care center in Toronto, Ontario between January 1, 2012, and June 1,
25 2019. The study group included individuals who had CM, and the control group included
26 individuals with fibroids who had a CD without removing their fibroids. The primary outcome
27 was the rate of blood products transfusion. Secondary outcomes were the need for hysterectomy
28 and estimated blood loss (EBL). Subgroup analyses were performed for fibroid size, previous
29 CD, and elective vs urgent CD. Logistic regression analysis was performed to assess for
30 confounders.

31 Results: Overall, 110 CM were compared with 152 CD. The overall transfusion rate for CM was
32 7.3% compared to 0.7% in the control group ($p = 0.005$). All procedures requiring transfusion
33 from both groups were performed $< 37^{0/7}$ weeks of gestation. In logistic regression analysis,
34 performing a myomectomy was not associated with a higher risk for transfusion. The only
35 factors associated with transfusion were preterm birth (aOR 14.43, $p=0.049$) and low pre-
36 operative hemoglobin (aOR 0.90, $p=0.02$). The median reported EBL was 800 mL for CM and
37 700 mL for controls ($p<0.001$). No individuals in either group required concomitant
38 hysterectomy. Subgroup analysis showed that fibroid size ≥ 5 cm and previous CD were not

39 associated with increased risk of transfusion among those who had a CM, while urgent CM was
40 significantly associated with the need for transfusion ($p=0.02$).

41 Conclusion: This study demonstrates that the transfusion rate was not significantly higher in
42 those undergoing CM at term, compared to those with fibroids undergoing CD without a
43 myomectomy.

44 INTRODUCTION

45 Uterine fibroids are common benign tumors, that originate from the smooth muscle layer of the
46 uterus¹. It is estimated that fibroids occur in over 70% of biologically female individuals by the
47 onset of menopause². Individuals with fibroids are often asymptomatic, however, symptoms may
48 include uterine bleeding, pelvic pain, pressure, and infertility³. There are multiple treatment
49 options including medical, surgical, or image-guided. Myomectomy and hysterectomy are the
50 mainstays of surgical treatment. While hysterectomy is a definitive treatment, myomectomy is
51 reserved for those individuals wishing to preserve fertility.

52 Fibroids are also common among pregnant individuals and are becoming more frequent as
53 maternal age increases. While they are often asymptomatic, they may cause pain, pressure, or
54 preterm labor. If left untreated, many of these individuals will require surgical treatment later in
55 life, and it is estimated that treatment will be required in 25% of individuals with fibroids².

56 Cesarean delivery (CD) presents a unique opportunity to simultaneously perform a myomectomy
57 with the CD, possibly preventing a second surgery in the future. Cesarean myomectomy (CM),
58 however, is controversial. It has historically been discouraged because of the risk of excessive
59 hemorrhage causing anemia or requiring blood products transfusion, the risk of unnecessary
60 hysterectomy, puerperal infection, and increased operative time⁴. However, more recent
61 literature has supported CM to be a safe procedure with only a small increase in operative time
62 and no increased risk of post-operative complications^{5,6}. Furthermore, there may be benefits of
63 doing a CM, such as a smaller uterine incision because the uterus/fibroid ratio is increased and
64 the fibroid cleavage planes are easier to find⁷. As well, the natural uterine contractibility and
65 involution of the postpartum period reduces hemorrhage⁸.

66 Although recent systematic reviews and meta-analyses of observational studies have provided
67 favorable evidence to support carrying out CM, the data is heterogeneous in terms of the control
68 groups and types of fibroids removed and there is potential bias from the included studies.
69 The purpose of this study was to therefore compare the surgical outcomes of individuals
70 undergoing CM compared to those with fibroids undergoing CD alone.

71 **METHODS**

72 We conducted a single-center retrospective cohort study of all CM performed between January 1,
73 2012, and June 1, 2019. A control group of individuals that underwent CD in which fibroids
74 were identified but not removed was evaluated over a similar period. These individuals were
75 identified from the hospital database and data was extracted from patient records.

76 Extracted data included demographics such as maternal age (years), parity, gestational age at
77 delivery (determined by first trimester ultrasound), previous myomectomy, and size and number
78 of fibroids removed. The primary outcome was the rate of blood products transfusion. Secondary
79 outcomes were the need for hysterectomy, length of surgery (minutes) and estimated blood loss
80 (EBL, mL, determined subjectively by the surgical team), and change in hemoglobin (Hb) from
81 pre-operative (within one month of surgery) to post-operative (day 1 after surgery). Individuals
82 with a history of a documented bleeding disorder, multiple gestation, pre-eclampsia,
83 chorioamnionitis, placenta previa, placenta accrete spectrum disorders, or abruption were
84 excluded. Subgroup analyses were performed comparing outcomes for individuals depending on
85 fibroid size (\geq or $<$ 5cm), previous CD, and elective vs urgent CD.

86 Statistical analysis was performed using SPSS version 28.0 (IBM, Armonk, NY, USA).

87 Continuous variables were analyzed using the Mann-Whitney U test, and categorical variables
88 using the chi-square or Fisher's exact test, as needed. A logistics regression analysis was
89 performed to account for potential confounders, and a sub-group analysis was performed as well
90 among the individuals who had a myomectomy. The significance level was determined at $p <$
91 0.05. This study was approved by the hospital Research Ethics Board (Project Identification
92 Number: 212-2019).

93 **RESULTS**

94 Overall, 262 individuals met the inclusion criteria and were included in the study: 110 (42%)
95 who underwent a myomectomy during their cesarean delivery (CM group), and 152 (58%) who
96 had fibroids that were not removed during their CD (CD group).

97 The participants in the CM group were characterized by a higher rate of previous surgery for
98 myomectomy, slightly lower gestational age at the time of delivery, and a higher rate of elective
99 procedure. No other demographic characteristics were found to be different between the groups
100 (Table 1).

101 As for the procedures, CM took approximately 13.5 minutes longer to complete compared with
102 regular CD (47.0 vs 60.5 minutes, $p<0.001$). The estimated blood loss was higher in the CM
103 group, as was the rate of post-procedure need for blood products transfusion (Table 1). Yet, the
104 difference between the hemoglobin level before and after the procedure was not significantly
105 different between the groups (21 mg/dL in the CM group vs. 20 mg/dL in the CD group,
106 $p=0.25$).

107 To account for potential confounders for the need for post-procedure transfusion, a logistic
108 regression model was calculated using the following factors: Myomectomy, pre-operative
109 hemoglobin level, preterm birth, maternal age, previous surgery for myomectomy, previous CD
110 and urgent vs. non-urgent procedure (Table 2). Pre-operative hemoglobin level and preterm birth
111 were found to be independent risk factors for transfusion, but myomectomy during the CD was
112 not (aOR 5.4. 95% CI 0.47-61.6, $p=0.18$).

113 Size of fibroid:

114 Out of the 110 individuals who had a myomectomy, 53 (48%) had a fibroid size less than 5 cm
115 (<5cm), and 57 (52%) had a fibroid size greater or equal to 5 cm (≥ 5 cm). Those with larger
116 fibroid size were characterized by a lower rate of previous surgery for myomectomy, their CM
117 took approximately 8 minutes longer, and their estimated blood loss was higher, compared with
118 the smaller fibroid group. However, the hemoglobin difference before and after the procedure,
119 and the rate of postpartum transfusion were not significantly different between the groups (Table
120 3a).

121 Previous cesarean section (CS):

122 Overall, of the individuals with CM, 81 individuals (74%) had no previous CD and 29 (26%) had
123 at least one previous CD. There was no significant difference in the hemoglobin decline from
124 before to after the procedure, or in the rate of postpartum transfusion between the groups (Table
125 3b).

126 Urgent versus elective procedure:

127 Of the individuals with CM, 41 (37%) participants had an urgent procedure and 69 (63%) had an
128 elective procedure. The urgent CM group was characterized by a higher rate of primiparity and a
129 lower gestational age at delivery (Table 3c). The procedure duration was not significantly
130 different between the two groups. The pre-operative hemoglobin and hemoglobin differences
131 from before to after surgery were also not significantly different between the two groups.
132 However, the estimated blood loss was higher by approximately 100mL in individuals with
133 urgent CM, the post-operative hemoglobin was lower by approximately 10mg/dL, and the rate of
134 post-procedure blood transfusion was higher among individuals with urgent CM (14.6% in
135 urgent CM group vs 2.9% in elective CM group, $p=0.02$) (Table 3c).

136

137 **DISCUSSION**

138 In this cohort of pregnant individuals with fibroids undergoing cesarean delivery, 42% had a
139 concurrent myomectomy at the time of delivery. Participants who underwent CM had a slightly
140 longer procedure duration than their counterparts who did not have a myomectomy during the
141 CD. Individuals in the CM group had a higher rate of post-procedure need for blood products
142 transfusion. However, when accounting for other factors that may impact the need for post-
143 procedure transfusion, the performance of a myomectomy was not found to be a risk factor for
144 transfusion. Fibroid size (fibroid size <5 cm versus \geq 5cm) and previous CD were not found to
145 impact post-procedure transfusion rates, while urgent (vs. elective) procedure was associated
146 with a higher rate of transfusion.

147 In our study, the CM group had a longer procedure duration of 13.5 minutes compared to the
148 CD. In systematic reviews and primary studies, procedure time was found to be longer in CM
149 than in CD alone^{5,6}. In a meta-analysis of 23 studies, the procedure duration was longer in CM
150 by 10.4 minutes, and in another meta-analysis (17 studies) it was on average 14.8 minutes longer
151 which is consistent with our study^{5,6}. This increased surgical time did not translate to a clinically
152 meaningful complication, and compared with the potential alternative, which is another surgical
153 procedure, is considerably more cost-effective in terms of operative room time, personnel, etc.

154 We found the mean decline in hemoglobin was not significantly different among participants
155 who had CM vs. CD. This is consistent with several retrospective cohort studies in the literature
156 that have also found no significant difference in the hemoglobin decline between CM and CD in
157 individuals with fibroids^{4,9-16}. However, two recent meta-analyses found that the mean change in
158 hemoglobin was of greater magnitude among CM compared to CD by a clinically insignificant

159 amount (0.27 gm% and 0.20g/dL differences between CM and CD individuals)^{5,6}. The larger
160 sample sizes in these studies (n=3960 and 4906 individuals respectively) could explain why a
161 statistically significant difference was found with a small effect size.

162 A large retrospective cohort study examining predictors of peripartum blood transfusion found
163 that earlier gestational age and pre-operative anemia (hematocrit <32%) were both significantly
164 associated with an increased odds of needing transfusion at the time of CD alone¹⁷. Several
165 retrospective cohort studies have found no difference in transfusion rates between CM and CD
166 ^{1,4,10,12,15,16,18,19}. Two studies reported that myomectomy was not associated with an increased risk
167 of blood loss, greater decline in hemoglobin, or increased risk of postpartum hemorrhage during
168 CD^{1,9}. In contrast, two recent meta-analyses found a higher rate of transfusion among CM
169 compared to CD (OR 1.47 and RR 1.45 respectively)^{5,6}. However, the outcomes of these meta-
170 analyses may be confounded by the factors identified in our study of pre-operative hemoglobin
171 and preterm birth.. So, although CM may appear to be associated with a higher rate of
172 transfusion in some studies, this association could be due to other factors independent of
173 myomectomy, which was highlighted in our study, such as pre-operative anemia and preterm
174 birth.

175 Fibroid size has been studied as a factor impacting the outcomes of CM. In our study, among
176 CM individuals, a larger fibroid size (≥ 5 cm) was associated with longer procedure duration and
177 higher estimated blood loss by 200mL, but no significant difference in transfusion rate. Several
178 studies have found that larger fibroid diameter was associated with increased blood loss events
179 such as postpartum hemorrhage^{1,9,18}, while other studies have found no significant difference in
180 transfusion rate or hemoglobin decline^{4,14-16}. The heterogeneity in results may be due to different
181 cutoff points for fibroid size in different studies, as well as the experience of the surgeons with

182 performing CM on large fibroids. In one retrospective cohort study by Lee, no significant
183 difference was found in transfusion rate comparing myomectomy for fibroids <5cm and 5-10 cm,
184 but a significantly higher rate of transfusion in individuals with fibroids >10cm was found²⁰.
185 Also, many studies did not specify whether the control group undergoing CD had fibroids, which
186 would lead to a bias in the results. In one retrospective study, the presence of fibroids larger than
187 7cm increased the rate of massive intra-operative bleeding regardless of whether myomectomy
188 was performed.²¹

189 The higher transfusion rate among urgent (versus elective) CM individuals in our analysis could
190 be explained by other confounding factors, since it was not found to be a predictor of transfusion
191 in the logistic regression comparing CD with CM. A retrospective cohort study found that
192 unplanned CD in the first stage of labor was not significantly associated with EBL>500mL or a
193 hemoglobin decline >20g/L in multivariate logistic regression analysis of individuals with
194 fibroids who underwent CD or CM⁹. However, it is possible that a non-elective procedure could
195 be a predictor in the CM group. So, although we cannot make any conclusions from this sub-
196 group analysis, it is possible that an urgent CM could be a higher risk for transfusion. This
197 should be documented in future studies as a potential confounding variable and surgeons should
198 be prepared for this possibility when undertaking urgent cesarean section that may necessitate a
199 myomectomy concurrently.

200 This study identified preterm birth and pre-operative hemoglobin as significant predictors of the
201 risk of needing transfusion among CD and CM individuals with fibroids. Pre-operative
202 hemoglobin levels should be optimized by clinicians throughout pregnancy to decrease the risk
203 of peripartum transfusion. Preterm birth cannot necessarily be modified and therefore in cases of
204 preterm birth and known myomectomy, physicians should have blood products available as the

205 risk of transfusion is higher. Additional precautions for hemostasis can be taken with individuals
206 who have fibroids and may require a CM, similar to methods used during abdominal
207 myomectomy such as uterine tourniquet²². We also found that when accounting for these factors,
208 myomectomy itself was not significantly associated with an increased risk of transfusion. This
209 contributes to the growing body of literature that is turning in favor of CM as a safe procedure
210 that does not cause additional blood loss risks.

211 There is heterogeneity in the literature on whether fibroid size impacts transfusion rate;
212 ultimately this may be a factor that varies based on the center and surgical expertise. Also,
213 fibroid location and blood conservation techniques can greatly impact blood loss and the need for
214 transfusion, as seen in the gynecology literature^{5,22}. Therefore, it is not surprising that there is
215 heterogeneity in previous studies. This remains an unanswered question and future systematic
216 reviews should address this with a subgroup analysis on fibroid sizes <5 cm compared to ≥5 cm
217 as these appear to be the categories used by most of the studies we found.

218 Future work should also concentrate on the adaptation of methods used to decrease
219 intraoperative blood loss that are currently used for myomectomy outside of pregnancy. Several
220 strategies have been identified to decrease intraoperative blood loss at the time of myomectomy:
221 temporary uterine artery occlusion with suture ligation, vascular clips, or peri-cervical
222 tourniquet; uterotonics, fibroid dissection with electrosurgical devices; and use of antifibrinolytic
223 agents.^{14,16,23,24} Use of a cell saver may also be considered if anticipating a large amount of blood
224 loss. It will be important to study these methods at the time of CS to determine if they are
225 adaptable from the gynecology literature.

226 One of the strengths of our study is that both groups had fibroids, in contrast to most previous
227 studies in which a comparison was made between individuals with fibroids who had a

228 myomectomy and those without fibroids who had a CD. Additionally, we included individuals
229 with large fibroids >5 cm; the largest fibroid included was 30cm in diameter. We also did a
230 subgroup analysis on the impact of previous CD and urgent CD on the outcomes of CM, which
231 we have only seen in one other study⁹. Finally, not all studies included intramural fibroids, while
232 our study included all types of fibroid locations. We also had 21 different surgeons in our center
233 carrying out CM which makes the results more generalizable compared to other studies where
234 only the most experienced surgeons may have been carrying out CM or it was unknown.

235 The main limitation of our study is its retrospective nature. We also lacked data on fibroid size
236 among the control individuals. Another limitation is the lack of data on long-term outcomes,
237 such as hospitalization duration, fibroid recurrence, uterine dehiscence, and post-surgical
238 adhesions. Also, fibroid location (intramural, subserosal, pedunculated) was not accounted for in
239 our study and was not described in many of the previous studies, which can bias the results. An
240 important aspect of performing CM is the decision-making surrounding proceeding with an
241 elective opportunistic myomectomy. The size of the fibroid, location, and blood loss during the
242 procedure may impact whether the decision is made to go ahead with the myomectomy after the
243 delivery of the infant. Therefore, caution must be taken not to generalize the results of our study
244 and others to all CMs, as it is prudent to take all of the fibroid and patient characteristics into
245 account before proceeding with an opportunistic CM.

246 **CONCLUSION**

247 In our study, there was no significant difference in transfusion rate between CD and CM once
248 other factors were accounted for. Preterm birth and pre-operative hemoglobin were the only
249 significant predictors of needing a transfusion. Larger fibroid size and previous CD did not
250 significantly impact transfusion rate among CM individuals, while urgent CD did. Overall, CM

251 is a safe procedure compared to CD in terms of blood loss, but pre-operative hemoglobin should
252 be optimized and blood conservation techniques utilized when possible, to decrease risk. CM
253 offers many advantages including avoiding a second surgery, a potentially smaller incision on
254 the uterus, better fibroid cleavage planes, and increased uterine contractility. Surgeon judgment
255 and appropriate skills need to be utilized to minimize any increased risks to the patient.

256

257 **TABLES**

258 **Table 1 - Characteristics**

Variable	CD (n=152)	CM (n=110)	p-value
Maternal age, y	35.5 [7]	37.0 [6]	0.05
Gravidity, n	2 [2]	2 [2]	0.34
Parity, n	0 [1]	0 [1]	0.67
Nulliparity, n(%)	78 (51.3)	68 (61.8)	0.09
Previous CS, n(%)	38 (25.0)	29 (26.4)	0.8
Previous myomectomy, n(%)	0 (0)	19 (17.3)	<0.001
Gestational age, weeks	38.8 [2.1]	38.4 [2.9]	0.01
Preterm birth, n(%)	29 (19.1)	31 (28.2)	0.08
Elective CS, n(%)	37 (24.3)	69 (62.7)	<0.001
Procedure duration, min	47.0 [17]	60.5 [27]	<0.001
Estimated blood loss, ml	700 [100]	800 [300]	<0.001
Pre-operative hemoglobin, mg/dL	126 [16]	121 [18]	<0.001

post-operative hemoglobin, mg/dL	107 [15]	100 [24]	<0.001
Hemoglobin difference, mg/dL	20 [11]	21 [11]	0.25
Need for postpartum transfusion, n(%)	1 (0.7)	8 (7.3)	0.005

259 Data is presented as median [Interquartile range] or as n(%)

260 CS – cesarean section;

261

262 **Table 2 – logistic regression, risk factors for transfusion**

Variable	Adjusted odds ratio	95% confidence interval	p-value
Myomectomy	5.39	0.47-61.6	0.18
Pre-operative hemoglobin (for every increase in 1mg/dL)	0.90	0.82-0.99	0.02
Preterm birth	14.43	1.01-206.93	0.049
Maternal age (every additional year)	0.95	0.75-1.18	0.62
Previous myomectomy	5.77	0.37-90.99	0.21

Previous CS (each additional CS)	1.21	0.23-6.52	0.82
Non-elective CS	3.13	0.17-57.55	0.44

263

264 **Table 3a – characteristics, only myomectomies, comparison based on size**

Variable	Fibroid < 5cm (n=53)	Fibroid >= 5cm (n=57)	p-value
Procedure duration, min	57 [21]	65 [27]	0.03
Estimated blood loss, ml	700 [100]	900 [300]	0.001
Pre-operative hemoglobin, mg/dL	121 [21]	121 [15]	0.68
post-operative hemoglobin, mg/dL	100 [25]	100 [21]	0.36
Hemoglobin difference, mg/dL	18 [14]	21 [16]	0.16
Need for postpartum transfusion, n(%)	3 (5.7)	5 (8.8)	0.53

265 Data is presented as median [Interquartile range] or as n(%)

266 No difference in other characteristics, except for previous myomectomy (26.4% in the small

267 fibroid group, and 8.8% in the large fibroid group)

268

269 **Table 3b – characteristics, only myomectomies, comparison based on previous CS**

Variable	No previous CS (n=81)	Previous CS (n=29)	p-value
Procedure duration, min	60 [27]	61 [27]	0.83
Estimated blood loss, ml	800 [300]	700 [275]	0.02
Pre-operative hemoglobin, mg/dL	121 [16]	125 [22]	0.26
post-operative hemoglobin, mg/dL	97 [21]	105 [21]	0.03
Hemoglobin difference, mg/dL	21 [14]	20 [18]	0.10
Need for postpartum transfusion, n(%)	3 (5.7)	5 (8.8)	0.53

270 Data is presented as median [Interquartile range] or as n(%)

271 No difference in other characteristics, except for preterm birth rate (34.6% in the no previous CS

272 group vs. 10.3% in the previous CS group) and elective procedure (50.6% in the no previous CS

273 group vs. 96.6 in the previous CS group).

274

275

276 **Table 3c – characteristics, only myomectomies, comparison based on elective vs. urgent**

Variable	Urgent (n=41)	Elective (n=69)	p-value
Procedure duration, min	58 [31]	62 [24]	0.43
Estimated blood loss, ml	900 [400]	800 [225]	0.02
Pre-operative hemoglobin, mg/dL	118 [17]	122 [17]	0.16
post-operative hemoglobin, mg/dL	94 [18]	104 [23]	0.02
Hemoglobin difference, mg/dL	23 [19]	20 [17]	0.15
Need for postpartum transfusion, n(%)	6 (14.6)	2 (2.9)	0.02

277 Data is presented as median [Interquartile range] or as n(%)

278 No difference in other characteristics, except for parity (78% of primiparous individuals in the
279 urgent group vs. 52.2% in the elective group) and gestational age (34.9 weeks in the urgent
280 group vs. 38.9% in the elective group)

281

282

283

284 **REFERENCES**

- 285 1. Zhao R, Wang X, Zou L, Zhang W. Outcomes of Myomectomy at the Time of Cesarean Section
286 among Pregnant Women with Uterine Fibroids: A Retrospective Cohort Study. *Biomed Res Int.*
287 2019;2019:1-6. doi:10.1155/2019/7576934
- 288 2. Stewart E, Cookson C, Gandolfo R, Schulze-Rath R. Epidemiology of uterine fibroids: a
289 systematic review. *BJOG An Int J Obstet Gynaecol.* 2017;124(10):1501-1512. doi:10.1111/1471-
290 0528.14640
- 291 3. Bedaiwy MA, Janiszewski P, Singh SS. A Patient Registry for the Management of Uterine
292 Fibroids in Canada: Protocol for a Multicenter, Prospective, Noninterventional Study. *JMIR Res*
293 *Protoc.* 2018;7(11):e10926. doi:10.2196/10926
- 294 4. Senturk M, Polat M, Doğan O, et al. Outcome of Cesarean Myomectomy: Is it a Safe Procedure?
295 *Geburtshilfe Frauenheilkd.* 2017;77(11):1200-1206. doi:10.1055/s-0043-120918
- 296 5. Huang Y, Ming X, Li Z. Feasibility and safety of performing cesarean myomectomy: a systematic
297 review and meta-analysis. *J Matern Neonatal Med.* 2022;35(13):2619-2627.
298 doi:10.1080/14767058.2020.1791816
- 299 6. Goyal M, Dawood AS, Elbohoty SB, et al. Cesarean myomectomy in the last ten years; A true
300 shift from contraindication to indication: A systematic review and meta-analysis. *Eur J Obstet*
301 *Gynecol Reprod Biol.* 2021;256:145-157. doi:10.1016/j.ejogrb.2020.11.008
- 302 7. Incebiyik A, Hilali NG, Camuzcuoglu A, Vural M, Camuzcuoglu H. Myomectomy during
303 cesarean: a retrospective evaluation of 16 cases. *Arch Gynecol Obstet.* 2014;289(3):569-573.
304 doi:10.1007/s00404-013-3019-1
- 305 8. Sparić R, Malvasi A, Kadija S, Babović I, Nejković L, Tinelli A. Cesarean myomectomy trends
306 and controversies: an appraisal. *J Matern Neonatal Med.* 2017;30(9):1114-1123.
307 doi:10.1080/14767058.2016.1205024

- 308 9. Dedes I, Schäffer L, Zimmermann R, Burkhardt T, Haslinger C. Outcome and risk factors of
309 cesarean delivery with and without cesarean myomectomy in women with uterine myomas. *Arch*
310 *Gynecol Obstet.* 2017;295(1):27-32. doi:10.1007/s00404-016-4177-8
- 311 10. El-refaie W, Hassan M, Abdelhafez MS. Myomectomy during cesarean section: A retrospective
312 cohort study. *J Gynecol Obstet Hum Reprod.* 2020;49(10):101900.
313 doi:10.1016/j.jogoh.2020.101900
- 314 11. Sparić R, Papoutsis D, Bukumirić Z, et al. The incidence of and risk factors for complications
315 when removing a single uterine fibroid during cesarean section: a retrospective study with use of
316 two comparison groups. *J Matern Neonatal Med.* 2020;33(19):3258-3265.
317 doi:10.1080/14767058.2019.1570124
- 318 12. Topçu HO, İskender CT, Timur H, Kaymak O, Memur T, Danişman N. Outcomes after cesarean
319 myomectomy versus cesarean alone among pregnant women with uterine leiomyomas. *Int J*
320 *Gynecol Obstet.* 2015;130(3):244-246. doi:10.1016/j.ijgo.2015.03.035
- 321 13. Kumar R R. The Utility of Caesarean Myomectomy as a Safe Procedure: A Retrospective
322 Analysis of 21 Cases with Review of Literature. *J Clin DIAGNOSTIC Res.* Published online 2014.
323 doi:10.7860/JCDR/2014/8630.4795
- 324 14. Akkurt MO, Yavuz A, Eris Yalcin S, et al. Can we consider cesarean myomectomy as a safe
325 procedure without long-term outcome? *J Matern Neonatal Med.* 2017;30(15):1855-1860.
326 doi:10.1080/14767058.2016.1228057
- 327 15. Özcan A, Kopuz A, Turan V, et al. Cesarean myomectomy for solitary uterine fibroids: Is it a safe
328 procedure? *Polish Gynaecol.* 2016;87(01):54-58. doi:10.17772/gp/57833
- 329 16. Kwon DH, Song JE, Yoon KR, Lee KY. The safety of cesarean myomectomy in women with
330 large myomas. *Obstet Gynecol Sci.* 2014;57(5):367. doi:10.5468/ogs.2014.57.5.367
- 331 17. Ahmadzia HK, Phillips JM, James AH, Rice MM, Amdur RL. Predicting peripartum blood

- 332 transfusion in women undergoing cesarean delivery: A risk prediction model. *PLoS One*.
333 2018;13(12):e0208417. doi:10.1371/journal.pone.0208417
- 334 18. Sparić R, Kadija S, Stefanović A, et al. Cesarean myomectomy in modern obstetrics: More light
335 and fewer shadows. *J Obstet Gynaecol Res*. 2017;43(5):798-804. doi:10.1111/jog.13294
- 336 19. Akbas M, Mihmanli V, Bulut B, Temel Yuksel I, Karahisar G, Demirayak G. Myomectomy for
337 intramural fibroids during caesarean section: A therapeutic dilemma. *J Obstet Gynaecol (Lahore)*.
338 2017;37(2):141-145. doi:10.1080/01443615.2016.1229272
- 339 20. Lee Y-E, Park S, Lee K-Y, Song J-E. Risk factors based on myoma characteristics for predicting
340 postoperative complications following cesarean myomectomy. *PLoS One*. 2023;18(3):e0280953.
341 doi:10.1371/journal.pone.0280953
- 342 21. Sei K, Masui K, Sasa H, Furuya K. Size of uterine leiomyoma is a predictor for massive
343 haemorrhage during caesarean delivery. *Eur J Obstet Gynecol Reprod Biol*. 2018;223:60-63.
344 doi:10.1016/j.ejogrb.2018.02.014
- 345 22. Miazga E, Benlolo S, Robertson D, Nensi A. The Use of Uterine Tourniquet to Decrease Blood
346 Loss and Transfusion Rate during Myomectomy: A Systematic Review and Meta-Analysis. *J*
347 *Minim Invasive Gynecol*. 2021;28(11):S148-S149. doi:10.1016/j.jmig.2021.09.293
- 348 23. Hickman LC, Kotlyar A, Shue S, Falcone T. Hemostatic Techniques for Myomectomy: An
349 Evidence-Based Approach. *J Minim Invasive Gynecol*. 2016;23(4):497-504.
350 doi:10.1016/j.jmig.2016.01.026
- 351 24. Kongnyuy EJ, Wiysonge CS. Interventions to reduce haemorrhage during myomectomy for
352 fibroids. *Cochrane Database Syst Rev*. 2014;2015(7). doi:10.1002/14651858.CD005355.pub5
353
354